BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...respectively. Kymera’s KT-474  is one of several IRAK4...
...IKZF1; LYF1) – IKAROS family zinc finger 1 IRAK4...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...in 1H21 for its lead program, oral IRAK4...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...next year. Kymera hopes to submit an IND in 1H21 for its lead program, oral IRAK4...
...it filed in June; it had hoped to sell 5 million shares at $14-$16. Targets IRAK4...
BioCentury | Jul 10, 2020
Deals

Data Bytes: Kymera-Sanofi deal is latest sign targeted degradation is growing up

...Euronext:SAN; NASDAQ:SNY) will pay Kymera Therapeutics Inc. $150 million upfront for protein degrader therapies targeting IRAK4...
...oral daily administration of its IRAK4 degraders is well tolerated and induces complete knockdown of IRAK4...
...retains global rights to its IRAK4 program in cancer. Kymera is responsible for advancing the IRAK4...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

...best molecule to bind the pair. Kymera’s most advanced program is a targeted degrader of IRAK4...
...a spectrum of auto-inflammatory diseases. The other two programs nearing the clinic are a second IRAK4...
...2019 deal with Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) (see “Vertex Moving Into Protein Degradation” ). Targets IRAK4...
BioCentury | Nov 14, 2019
Emerging Company Profile

Cedilla: degrading proteins by modulating protein stability

...Inc., Cullgen Inc., Kymera Therapeutics Inc., Nurix Therapeutics Inc. and Plexium Inc. Kymera has an IRAK4-targeting...
BioCentury | Oct 23, 2019
Clinical News

Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

...C4 Therapeutics Inc., Kymera Therapeutics LLC, Cedilla Therapeutics Inc. and Cullgen Inc. Kymera has an IRAK4-targeting...
...ER - Estrogen receptor; HER2 - Epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu); IRAK4...
BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

...Pegasus can reduce the time and cost of discovery. The company has selected scaffolding protein IRAK4...
...transcription factor STAT3 as its first targets. Kymera reported that lead program KYM-001 selectively degraded IRAK4...
...apoptosis in activated B cell-like diffuse large B cell lymphoma (DLBCL) cell lines, whereas an IRAK4...
BioCentury | Apr 11, 2019
Emerging Company Profile

Nurix: Two sides of protein degradation

...other degraders in preclinical testing for cancers and neurodegenerative diseases. Kymera Therapeutics Inc. has an IRAK4-targeting...
...Targets Btk - Bruton’s tyrosine kinase Cbl-b - Casitas B cell lymphoma-b CRBN - Cereblon IRAK4...
Items per page:
1 - 10 of 55